AllianceBernstein
VBIV

AllianceBernstein’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

AllianceBernstein’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-6,827
Closed -$62.1K – 3272
2023
Q1 		$62.1K Hold
6,827
– – ﹤0.01% 3079
2022
Q4 		$80.1K Buy
6,827
+530
+8% +$9.35K ﹤0.01% 3136
2022
Q3 		$133K Buy
6,297
+567
+10% +$15.3K ﹤0.01% 3096
2022
Q2 		$139K Buy
5,730
+1,260
+28% +$42.9K ﹤0.01% 3087
2022
Q1 		$223K Buy
4,470
+20
+0.4% +$988 ﹤0.01% 2967
2021
Q4 		$312K Hold
4,450
– – ﹤0.01% 2932
2021
Q3 		$415K Sell
4,450
-1,370
-24% -$130K ﹤0.01% 2830
2021
Q2 		$585K Buy
5,820
+2,210
+61% +$215K ﹤0.01% 2751
2021
Q1 		$337K Sell
3,610
-1,300
-26% -$132K ﹤0.01% 2851
2020
Q4 		$405K Sell
4,910
-4,317
-47% -$368K ﹤0.01% 2690
2020
Q3 		$792K Sell
9,227
-2,933
-24% -$342K ﹤0.01% 2286
2020
Q2 		$1.13M Buy
12,160
+7,033
+137% +$387K ﹤0.01% 2144
2020
Q1 		$146K Buy
5,127
+2,124
+71% +$82.6K ﹤0.01% 2882
2019
Q4 		$124K Hold
3,003
– – ﹤0.01% 3004
2019
Q3 		$42K Sell
3,003
-157
-5% -$3.29K ﹤0.01% 3133
2019
Q2 		$111K Buy
+3,160
New +$171K ﹤0.01% 3064

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein's VBIV Position: Q2 2023 in Review

AllianceBernstein sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 6,827 shares — an estimated $62.1K sold.

AllianceBernstein first reported a position in VBIV in Q2 2019 and held it in 16 quarters. The position peaked at $1.13M in Q2 2020. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

  • AllianceBernstein reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
  • AllianceBernstein sold 6,827 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $62.1K.
  • AllianceBernstein first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2019 and held it in 16 quarters.
  • AllianceBernstein's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $1.13M in Q2 2020.
  • 46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on AllianceBernstein's 13F filing for Q2 2023, filed 15 Aug 2023.